Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Breast Neoplasms 1

Interventions

pembrolizumab 4Paclitaxel 2vocimagene amiretrorepvec 1stenoparib 1olaparib 1mirabegron 1epacadostat 1durvalumab 1ciforadenant 1cemiplimab 1atezolizumab 1advexin 1Temozolomide 1Rituximab 1Pharmacogenomic Variants 1Nivolumab 1LTX-315 1Ipilimumab 1IACS-010759 1HMPL-013 1Gemcitabine 1Fluorodeoxyglucose F18 1Flucytosine 1Carboplatin 1Capecitabine 1CPI-006 1Brentuximab Vedotin 1Bendamustine Hydrochloride 1Antibodies 1AZD5153 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × AZD5153 × Lymphoid × Clear all
NCT03205176 2021-05-06

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

AstraZeneca

Phase 1 Completed
49 enrolled
BreastGastrointestinalGenitourinaryGynecologicLymphoid

Breast Neoplasms, Lymphoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡